epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Alli
    orlistat
  • remove Oxtellar XR
    oxcarbazepine

multicheck MultiCheck Results - 0 Interaction

Smiley face Smiley face

Additional Considerations

Smiley face Smiley face orlistat in Alli

caution advised with concurrent oral narrow therapeutic index drugs with concerns for loss of efficacy; orlistat may decr. absorption of some oral drugs

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information